

## News Release

### **For Immediate Release**

October 16, 2020

### **For more information contact:**

Heather Medwick  
heather@cytophage.com

### **Winnipeg-made antibiotic alternative attracting international attention.**

Momentum is building this month at Winnipeg's Cytophage Inc., as Dr. Steven Theriault, CEO, will be featured on the Interactive Investment forum - BioPub. It's the fourth notable presentation of its kind this Fall for Theriault. The forum provides investors unfettered live access to executives from biotech companies that have evoked editorial attention.

This follows on the heels of Dr. Theriault's presentation at the World Anti-Microbial Resistance (AMR) Congress - the world's largest AMR gathering of stakeholders combating antimicrobial resistance, including governments, academia and industry representatives. Dr. Theriault presented on the use of bacteriophage to reduce antibiotic use in feed animals (chickens, swine and cattle).

Cytophage also presented recently at the Bacteriophage Therapy Summit; and Investing for a Cure Conference earlier in September.

"In the wake of Covid and all the medical, political and economic lessons we're learning, the international bio-science industry seems hungry for the next generation of innovation," says Dr. Theriault.

"Taking part in events like these is important in the evolution of bacteriophage. Every time we have the opportunity to get in front of peers and industry leaders and share our approach, our work is subjected to new feedback and we are opened to new opportunities, both of which support our strength and our growth."

The strength and growth of solutions like Cytophage's are important to all of us. The World Health Organization (WHO) predicts that by 2050, 10 million people will be killed by antibiotic resistant superbugs - every year. Considering what we have learned in 2020, it is clear the effect this will have on people's lives, the global economy and political stability.

Today, 80% of antibiotics globally are used in agriculture, so reducing antibiotic use in the feed animal population as soon as possible is paramount to sidelining this dire prediction. Part of a large and dynamic agricultural and biological science community in Winnipeg, Cytophage Inc. has developed a unique process for delivering tailor-made bacteriophages to replace antibiotics. These bacteriophages are inexpensive, quick to produce, harmless to humans and animals, better for the environment and highly effective against targeted bacteria. Bacteriophages can also be an important tool to prevent and treat bacterial infections and contaminations.

In 2018, Cytophage won the International Nutreco Feed Tech Challenge for their breakthrough innovation to help feed the world, and in 2019 Cytophage was selected for the TechConnect US Defense Innovation Award for their work on the use of bacteriophages against battlefield infections.

"It has taken some time to gain this momentum," adds Dr. Theriault. "But our team has been working diligently for years on this solution because we know it's value. We have harnessed nature's elegant, sophisticated approach to eliminating bacterial infection and contamination and now, we have the capacity to make it available for thousands of applications. From here, our shared future looks a bit brighter."

-30-